Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EBT (2018 - 2025)

Historic EBT for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$17.7 million.

  • Whitehawk Therapeutics' EBT fell 4106.02% to -$17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.2 million, marking a year-over-year decrease of 6725.19%. This contributed to the annual value of -$63.7 million for FY2024, which is 315.37% up from last year.
  • According to the latest figures from Q3 2025, Whitehawk Therapeutics' EBT is -$17.7 million, which was down 4106.02% from -$52.8 million recorded in Q2 2025.
  • Whitehawk Therapeutics' EBT's 5-year high stood at -$1.5 million during Q2 2021, with a 5-year trough of -$87.1 million in Q3 2021.
  • Its 5-year average for EBT is -$20.3 million, with a median of -$16.0 million in 2021.
  • Its EBT has fluctuated over the past 5 years, first crashed by 291238.33% in 2021, then surged by 8338.0% in 2022.
  • Over the past 5 years, Whitehawk Therapeutics' EBT (Quarter) stood at -$16.0 million in 2021, then grew by 12.93% to -$13.9 million in 2022, then dropped by 16.86% to -$16.3 million in 2023, then decreased by 12.32% to -$18.3 million in 2024, then increased by 3.16% to -$17.7 million in 2025.
  • Its EBT stands at -$17.7 million for Q3 2025, versus -$52.8 million for Q2 2025 and -$14.4 million for Q1 2025.